TABLE 1

Basic genetic, structural and pharmacological properties of dopamine receptor subtypes

The table was compiled from information presented in review articles (Niznik and Van Tol, 1992; Sibley and Monsma, 1992; Sokoloff et al., 1992a; Civelli et al., 1993; Missale et al., 1998; Vallone et al., 2000; Seeman, 2006; Rankin et al., 2010) and from the references cited therein.

Dopamine Receptor SubtypeD1D2D3D4D5
Gene symbolDRD1DRD2DRD3DRD4DRD5
Chromosomal gene map locus5q35.111q23.13q13.311p15.54p16.1
Number of introns in the coding regionNone653None
PseudogenesNoneNoneNoneNoneDRD5P1, DRD5P2
Presence of splice variantsNoneYes
D2S, D2L
YesYesNone
Number of amino acids446D2S, 414; D2L, 443400387477
Molecular weight49,300D2S, 47,347; D2L, 50,61944,22541,48752,951
G protein couplings, Gαolfi, Gαoi, Gαoi, Gαos, Gαq
Selective agonistsFenoldopam, SKF-38393, SKF-81297Bromocriptine, pergolide, cabergoline, ropinirole7-OH-DPAT, pramipexole, rotigotine, (+)-PD-128907A-412997, ABT-670, PD-168,077None
Selective antagonistsSCH-23390, SCH-39166, SKF-83566Haloperidol, spiperone, raclopride, sulpiride, risperidoneNafadotride, GR 103,691, GR 218,231, SB-277011AA-381393, FAUC 213, L-745,870, L-750,667None
  • 7-OH-DPAT, hydroxy-2-dipropylaminotetralin; A-381393, 2-[4-(3,4-dimethylphenyl)piperazin-1-ylmethyl[-1H benzimidazole; A-412997, N-(3-methylphenyl)-2-(4-pyridin-2-ylpiperidin-1-yl)acetamide; ABT-670, 3-methyl-N-(1-oxy-3′,4′,5′,6′-tetrahydro-2′H-[2,4′-bipyridine]-1′-ylmethyl)benzamide; FAUC 213, 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine; GR 218,231, (+)-(2R)-1,2,3,4-tetrahydro-6-[[(4-methoxyphenyl)sulfonyl[methyl]-N,N-dipropyl-2-naphthalenamine; GR 103,691, 4′-acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1′-biphenyl]-4-carboxamide; L-745,870, 3-(4-[4-chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine; L-750,667, 3-[4-(4-iodophenyl)piperazin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine; PD-128907, (4aR,10bR)-3,4a,4,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin-9-ol; PD-168,077, N-{[4-(2-cyanophenyl)piperazin-1-yl]methyl}-3-methylbenzamide-(2Z)-but-2-enedioic acid; ; SB-277011A, N-{trans-4-[2-(6-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl]cyclohexyl}quinoline-4-carboxamide; SCH-39166, (−)-trans-6,7,7α,8,9,13β-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho[2,1-b]azepine; SKF-38393, 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; SKF-81297, (±)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; SKF-83566, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol.